Syndax-Incyte Partnered Chronic Graft-Versus-Host Disease Achieves Primary Endpoint In Pivotal Trial, FDA Submission Planned By 2023 End
Portfolio Pulse from Vandana Singh
Syndax Pharmaceuticals and Incyte Corporation announced positive topline data from the AGAVE-201 trial of axatilimab, a treatment for chronic graft-versus-host disease. The trial achieved its primary endpoint across all cohorts. Based on these results, the companies plan to submit a Biologics License Application to the FDA by the end of 2023. However, shares of both companies are down in recent trading.
July 24, 2023 | 3:10 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Incyte Corporation's shares are down by 0.80% despite the positive trial results.
The positive trial results are a significant development for Incyte, indicating potential future revenue from axatilimab. However, the stock price has fallen, possibly due to market factors or investor sentiment not reflected in the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100
NEGATIVE IMPACT
Despite positive trial results, Syndax Pharmaceuticals' shares are down by 1.03%.
The positive trial results are a significant development for Syndax, indicating potential future revenue from axatilimab. However, the stock price has fallen, possibly due to market factors or investor sentiment not reflected in the news.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100